Vaccine (Recombinant protein vaccine) · Immune activation · developed by Pfizer
RSVpreF is a vaccine directed at the prefusion F protein of respiratory syncytial virus, intended to induce immune responses against the virus. It is being studied for the prevention of respiratory syncytial virus (RSV) disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07839871 | Phase 3 | Respiratory Syncytial Virus (RSV) | Recruiting | PFE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Respiratory Syncytial Virus (RSV)
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →